

Annah S Rolig

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/995697/publications.pdf>

Version: 2024-02-01

14
papers

792
citations

1163117

8
h-index

1281871

11
g-index

15
all docs

15
docs citations

15
times ranked

1197
citing authors

#	ARTICLE	IF	CITATIONS
1	Individual Members of the Microbiota Disproportionately Modulate Host Innate Immune Responses. <i>Cell Host and Microbe</i> , 2015, 18, 613-620.	11.0	135
2	Interhost dispersal alters microbiome assembly and can overwhelm host innate immunity in an experimental zebrafish model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 11181-11186.	7.1	131
3	The role of Galectin-3 in modulating tumor growth and immunosuppression within the tumor microenvironment. <i>Oncolmmunology</i> , 2018, 7, e1434467.	4.6	131
4	The enteric nervous system promotes intestinal health by constraining microbiota composition. <i>PLoS Biology</i> , 2017, 15, e2000689.	5.6	126
5	Spatial and Temporal Features of the Growth of a Bacterial Species Colonizing the Zebrafish Gut. <i>MBio</i> , 2014, 5, .	4.1	93
6	A bacterial immunomodulatory protein with lipocalin-like domains facilitates host-bacteria mutualism in larval zebrafish. <i>ELife</i> , 2018, 7, .	6.0	46
7	Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor. , 2021, 9, e002371.		44
8	Galectin-3 inhibition with belapectin combined with anti-OX40 therapy reprograms the tumor microenvironment to favor anti-tumor immunity. <i>Oncolmmunology</i> , 2021, 10, 1892265.	4.6	21
9	NKTR-214 immunotherapy synergizes with radiotherapy to stimulate systemic CD8+ T cell responses capable of curing multi-focal cancer. , 2020, 8, e000464.		20
10	Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8+ T cell cytotoxicity over BEMPEG+RT. , 2022, 10, e004218.		12
11	Arginase Therapy Combines Effectively with Immune Checkpoint Blockade or Agonist Anti-OX40 Immunotherapy to Control Tumor Growth. <i>Cancer Immunology Research</i> , 2021, 9, 415-429.	3.4	11
12	Enhancing the Generation of Eomeshi CD8+ T Cells Augments the Efficacy of OX40- and CTLA-4-Targeted Immunotherapy. <i>Cancer Immunology Research</i> , 2021, 9, 430-440.	3.4	8
13	Intratumoral Electroporation of Plasmid Encoded IL12 and Membrane-Anchored Anti-CD3 Increases Systemic Tumor Immunity. <i>Molecular Cancer Research</i> , 2022, 20, 983-995.	3.4	8
14	Intracellular Galectin-3 Is Essential for OX40-Mediated Memory CD8+ T Cell Development. <i>Journal of Immunology</i> , 2020, 205, 1857-1866.	0.8	6